Shark cartilage
This article was originally published in The Tan Sheet
Executive Summary
Saint Foy, Quebec-based AEterna Labs selected by the National Cancer Institute to conduct Phase III trials of the biotech lab's angiogenesis inhibitor AE-941/Neovastat, a liquid shark cartilage extract. The trials will attempt to evaluate the agent in the treatment of cancer, and will be conducted in hospitals throughout the U.S. and Canada beginning in early 1999. The studies are to include a double-blind, placebo-controlled trial administered to several hundred cancer patients